Clinical trial
Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant…
NCT00225901 · Kyoto University, Graduate School of Medicine, Other · Unknown status
Key facts
| NCT number | NCT00225901 |
|---|---|
| Title | Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure |
| Official title | Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant and Late-Onset Hepatic Failure |
| Lead sponsor | Kyoto University, Graduate School of Medicine, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Liver Failure, Acute |
| Intervention type | Drug |
| Interventions | Recombinant human hepatocyte growth factor |
| Enrollment | 16 |
| Start date | Sep 1, 2005 |
| First posted | Sep 26, 2005 |
| Last update posted | Sep 26, 2005 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: